top of page
News, Events and Updates
Search
Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD
Oct 13, 2021
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
Sep 26, 2021
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access
Sep 26, 2021
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 19, 2021
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 8, 2021
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome
Aug 26, 2021
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Aug 12, 2021
Anavex Life Sciences to Announce Fiscal 2021 3rd Quarter Financial Results on Thurs., Aug. 12, 2021
Aug 4, 2021
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
Aug 3, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jul 28, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS
Jun 27, 2021
11
12
13
14
15
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
